Prof. Giorgio Sartor

These documents can be accessed ONLY by registered users

HOME Anthropology Alcoholism Bacterial and fungine diseases Cancer Clinical practice Drugs Inflammatory processes Environment LEUKEMIA Neurology Skeleton Viral diseases COVID-19 AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia A novel mechanism for imatinib mesylate–induced cell death of BCR-ABL–positive human leukemic cells: caspase-independent, necrosis-likeprogrammed cell death mediated by serine protease activity Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Chronic Myelogenous Leukemia: A Concise Update Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation Epidermal growth factor stimulates tyrosine phosphorylation in the neonatal mouse: Association of a Mr 55,000 substrate with the receptor Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hairfollicle development and skin structure Familial whole-arm translocations (1;19), (9;13), and (12;21): a review of 101 constitutional exchanges Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Imatinib mesylate is the first-line agent for the treatment of Philadelphia (Ph) chromosome–positive (Ph-pos; that is, Bcr-Abl translocation–positive) chronic myeloid leukemia (CML) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome Mechanisms of cutaneous toxicities to EGFR inhibitors New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumorcells and normal human keratinocytes Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone PROGRESS WITH CHRONIC MYELOGENOUS LEUKEMIA: A Personal Perspective over Four Decades Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specifi c BCR-ABL mutants in Ph+ ALL Second generation inhibitors of BCR-ABL for the treatment of imatinib resistant chronic myeloid leukaemia Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance Systemic sclerosis after interferon-alfa therapy for myelo proliferative disorders Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype The discovery of receptor tyrosine kinases: targets for cancer therapy The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor Velvet, a Dominant Egfr Mutation That Causes Wavy Hair and Defective Eyelid Development in Mice What Kind of Rash Is It? Deciphering the Dermatologic Toxicities of Biologic and Targeted Therapies Archeology Biochemistry Biology Chemistry Earth Sciences MEDICINE Physics Political Sciences Space Sciences Tools for sciences Books
			gs © 2001-2023 20210909